Interview: Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic

    loading  Checking for direct PDF access through Ovid


Nick Giannoukakis speaks to Katie Lockwood, Assistant Commissioning Editor

Nick Giannoukakis began his medical career at McGill University (Montreal, Canada), receiving his BSc and PhD in 1992 and 1997, respectively. From there, he went on to study a postdoctoral fellowship at the University of Pittsburgh School of Medicine (PA, USA) where he now holds the position of Associate Professor of Pathology and Immunology. He is a current member of the Division of Experimental Pathology and a member of the Cellular and Molecular Pathology Graduate Training Program. He teaches topics on pancreas and thyroid development and pathology, as well as cell and gene therapy approaches in diabetes mellitus in a number of courses offered by the department and also directs the ‘Introduction to Immunobiotherapeutics’ course in the Department of Immunology. He has mentored graduate, MD/PhD students, as well as clinical fellows. Giannoukakis is also one of the founders of DiaVacs® (NJ, USA), a biotechnology entity leveraging dendritic cell therapy for autoimmunity.

Related Topics

    loading  Loading Related Articles